Loading...

CTSO CYTOSORBENTS CORP US FDA Inspections 8-K Filing

CYTS

CTS

CYTOSORBENTS CORP

(CTSO)

2024 8-K

Listing Compliance Extension

Financial Results Update

Financial Results Released

Nasdaq Compliance Notice

Regulatory Update

FDA Appeal Outcome

Financial Statements

Product Updates

Regulatory Compliance

Regulatory Compliance

Rights Offerings

Financial Statements

Regulatory Compliance

Management Appointment

Management Change

Warrant Extension

Financial Results

Financial Restatement

Earnings Update

Earnings Update

Warrant Expiration

Rights Offering Results

Financial Results

Rights Offering

Rights Offering

Financial Results

Equity Offering

Financial Results & FDA

Royalty Agreement Update

Management Changes

Financial Results

Compliance regained with Na...

Annual Meeting of Stockholders

Financial Results Announcement

Bylaws Amendments

Salary Reduction Program an...

Financial Results Announcement

Update on Clinical Trial Da...

Securities Purchase Agreement

Financial Results Announcement

Participation in EACTS Annu...

Employment Agreement

Management Changes

Investigation into CFO Conduct

Financial Results Announcement

Annual Meeting of Stockholders

Financial Results Announcement

Enrollment in Clinical Trial

Departure of Directors

Consulting Agreement with R...

Financial Results Announcement

Financial Update

External Links:

CytoSorbents Corporation announced preliminary financial results for Q3 2024 and submitted a marketing application for its DrugSorb-ATR device to the FDA, which has received Breakthrough Device Designation.

AI Assistant

CYTOSORBENTS CORP

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.